Pharmaceuticals Indonesia

Indonesia Diabetes Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Indonesia Diabetes Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Indonesia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $294.9 Mn Placeholder estimate
Estimate 2025 $318.2 Mn 0.4% of the global market
Projected 2034 $630.8 Mn 98.2% Adds $312.6 Mn over 9 forecast years
CAGR 2025–2034 7.9% Faster than 50% of 2 Pharmaceuticals markets here
Key players 6 +1
  • Indonesia is 0.41% of the global market.
  • In APAC, the largest is China at $6.39 Bn.
  • Fastest growing: India at 10% a year.
  • Indonesia ranks 7th of 14 by size in APAC.

Market size projection

Indonesia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$312.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Diabetes Drugs Market market size by year, Indonesia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $294.9 Mn — —
2025 (base) $318.2 Mn +$23.3 Mn —
2026 (forecast) $343.3 Mn +$25.1 Mn +7.9%
2027 (forecast) $370.4 Mn +$27.1 Mn +16.4%
2028 (forecast) $399.7 Mn +$29.3 Mn +25.6%
2029 (forecast) $431.3 Mn +$31.6 Mn +35.5%
2030 (forecast) $465.4 Mn +$34.1 Mn +46.3%
2031 (forecast) $502.1 Mn +$36.8 Mn +57.8%
2032 (forecast) $541.8 Mn +$39.7 Mn +70.3%
2033 (forecast) $584.6 Mn +$42.8 Mn +83.7%
2034 (forecast) $630.8 Mn +$46.2 Mn +98.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Indonesia Diabetes Drugs Market Analysis at a glance
Market size, 2025$318.2 Mn placeholder estimate
Forecast, 2034$630.8 Mn placeholder estimate
Growth (CAGR), 2025–20347.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, route and end user (see all)
Key playersNovo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, Merck & Co., Inc. and 1 more (see all)
Regulator in IndonesiaBPOMSource: National Agency of Drug and Food Control (BPOM). Checked 19 Nov 2026.
Active clinical trials21 in IndonesiaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Indonesia. Retrieved 21 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Indonesia Diabetes Drugs Market Analysis Executive Summary

Diabetes drugs lower blood sugar in people with type 1 or type 2 diabetes, including insulin, pills and injectable GLP-1 medicines.

Key segments of the diabetes drugs market include drug class (Insulin, GLP-1 Agonists and SGLT2 Inhibitors) and route (Oral and Injectable).

Bar chart: Indonesia Diabetes Drugs market size, 2024–2034, placeholder estimates. $294.9 Mn in 2024, $318.2 Mn in 2025 and $630.8 Mn in 2034, 7.9% CAGR.
Indonesia Diabetes Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Indonesia Diabetes Drugs Market Dynamics

Market Growth Drivers

Rising numbers of people with diabetes, a shift to tools that track and deliver treatment automatically, and more insurance cover are driving the diabetes drugs market.

Opportunity

Connected devices, lower-priced sensors and new insulins and pills give the diabetes drugs market room to grow.

Market Restraints

High costs for people without cover, price competition and uneven access to care in low-income countries hold back the diabetes drugs market.

Competitive Landscape for Diabetes Drugs Market in Indonesia

The diabetes drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Diabetes Drugs Market in Indonesia

Diabetes Drugs in Indonesia: rules, payment and research

The National Agency of Drug and Food Control (BPOM) registers medicines before sale.⁠[1] The national health insurance scheme (JKN), run by BPJS Kesehatan, covers most of the population.⁠[2] ClinicalTrials.gov lists 21 studies on Diabetes Drugs that are recruiting, active or about to start in Indonesia.⁠[3] Diabetes (ages 20–79): 11.3% of people 20–79 in 2024, the latest World Bank figure for Indonesia.⁠[4]

[1] National Agency of Drug and Food Control (BPOM). Checked 19 Nov 2026.

[2] BPJS Kesehatan. Checked 19 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Indonesia. Retrieved 21 Nov 2026.

[4] World Bank Open Data, Diabetes (ages 20–79) (% of people 20–79). Retrieved 21 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for diabetes drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Indonesia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Diabetes Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Diabetes Drugs in context

Indonesia compared

  • Diabetes (ages 20–79): 11.3% of people 20–79 (2024). World: 10.8% of people 20–79 (2024). 7th highest of the 18 countries we cover in APAC.[1]
  • Health spending per person: 132 US$ per person (2023). World: 1,317 US$ per person (2023). 11th highest of the 17 countries we cover in APAC.[2]
  • Doctors: 0.52 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 16th highest of the 17 countries we cover in APAC.[3]

[1] World Bank Open Data, Diabetes (ages 20–79) (% of people 20–79). Retrieved 21 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 20 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Diabetes Drugs market in Indonesia?
Placeholder estimate: about $318.2 Mn in 2025, rising to about $630.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Diabetes Drugs market in Indonesia growing?
Placeholder estimate: about 7.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Diabetes Drugs market report cover?
The report splits the market by drug class (Insulin, GLP-1 Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors and more), route (Oral, Injectable) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Diabetes Drugs market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, Merck & Co., Inc. and Boehringer Ingelheim GmbH.
What is driving the Diabetes Drugs market?
Rising numbers of people with diabetes, a shift to tools that track and deliver treatment automatically, and more insurance cover are driving the diabetes drugs market.
Who regulates Diabetes Drugs in Indonesia?
The National Agency of Drug and Food Control (BPOM) registers medicines before sale. Source: National Agency of Drug and Food Control (BPOM). Checked 19 Nov 2026.
How is healthcare paid for in Indonesia?
The national health insurance scheme (JKN), run by BPJS Kesehatan, covers most of the population. Source: BPJS Kesehatan. Checked 19 Nov 2026.
How many clinical trials on Diabetes Drugs are running in Indonesia?
21 studies are recruiting, active or about to start in Indonesia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Indonesia. Retrieved 21 Nov 2026.
What does World Bank report for Indonesia?
Diabetes (ages 20–79): 11.3% of people 20–79 in 2024, the latest World Bank figure. Source: World Bank Open Data, Diabetes (ages 20–79) (% of people 20–79). Retrieved 21 Nov 2026.
How many people in Indonesia are 65 or older?
7.5% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 21 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Indonesia

See all

Related on diabetes

See the topic